Advancing diagnostics to improve public health.

A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than
150 countries through 39 subsidiaries and a large network of distributors. In 2007, revenues reached
€1.063 billion with 84% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of
disease and contamination to improve patient health and ensure consumer safety. Our products are used
for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies
and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food,
pharmaceutical and cosmetic products.
bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).